using genomic alterations to predict relapse following immunotherapy in multiple myeloma
Published 6 months ago • 71 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
2:17
session highlights: practical aspects of immunotherapy in multiple myeloma
-
1:29
managing toxicities associated with immunotherapy in multiple myeloma
-
5:49
magnetismm-3 extended follow up results: elranatamab monotherapy in r/r multiple myeloma
-
2:35
resistance to immunotherapy in multiple myeloma: mechanisms & monitoring
-
2:20
the role of myeloma b-cells & pre-plasma cell progenitors in disease relapse following therapy
-
3:15
what is the best diet for myeloma patients to build a strong immune system?
-
9:25
mgus diagnosis: a step-by-step approach
-
12:26
treating ultra high risk myeloma patients in a unique uk study | martin kaiser, md | ash 2021
-
1:53
factors to consider for the optimal management of relapse in multiple myeloma
-
1:57
sequencing immunotherapies in multiple myeloma
-
2:26
the role of immunotherapy in multiple myeloma
-
3:11
sequencing immunotherapies in multiple myeloma
-
4:56
genome sequencing in multiple myeloma
-
2:42
enhancing outcomes in multiple myeloma with immune-based strategies
-
2:46
managing patients with high-risk myeloma
-
2:54
using whole genome sequencing to track early events in multiple myeloma
-
2:28
b-cells and pre-plasma cells are important reservoirs responsible for relapse in multiple myeloma
-
3:10
immunotherapy for the treatment of multiple myeloma
-
2:44
myeloma qol through induction and maintenance
-
3:00
processes leading to the development of hyperdiploidy in multiple myeloma
-
2:20
treatment sequencing in multiple myeloma: a multitude of options
-
1:03
an insight into the sequencing of immunotherapies in adults with all